

ABIOMED INC
Form 4
May 12, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Howley Michael G

(Last) (First) (Middle)

C/O ABIOMED, INC., 22 CHERRY HILL DRIVE

(Street)

DANVERS, MA 01923

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABIOMED INC [ABMD]

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
VP, Global Sales & Marketing

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | Price | |
| Common Stock, \$.01 par value | 05/08/2015 | | M | | 14,301 | A \$ 5.23 | 97,601 D |
| Common Stock, \$.01 par value | 05/08/2015 | | S ⁽⁴⁾ | | 2,701 ⁽⁴⁾ | D \$ 64.1597 ⁽⁵⁾ | 94,900 D |
| Common Stock, \$.01 par value | 05/08/2015 | | S ⁽⁴⁾ | | 3,032 ⁽⁴⁾ | D \$ 65.1294 ⁽⁶⁾ | 91,868 D |

Edgar Filing: ABIOMED INC - Form 4

| | | | | | | | |
|------------------------------|------------|------------------------|--------------------------------|---|--|--------|---|
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | <u>1,593</u> ₍₄₎ | D | \$ <u>66.3304</u> ₍₇₎ | 90,275 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | <u>4,068</u> ₍₄₎ | D | \$ <u>67.3335</u> ₍₈₎ | 86,207 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | <u>2,303</u> ₍₄₎ | D | \$ <u>67.8776</u> ₍₉₎ | 83,904 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 544 <u>(4)</u> | D | \$ <u>69.0306</u> ₍₁₀₎ | 83,360 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 60 <u>(4)</u> | D | \$ <u>69.81</u> ₍₁₁₎ | 83,300 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 274 <u>(4)</u> | D | \$ <u>64.1598</u> _{(12) (19)} | 83,026 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 307 <u>(4)</u> | D | \$ <u>65.1294</u> _{(13) (19)} | 82,719 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 162 <u>(4)</u> | D | \$ <u>66.3304</u> _{(14) (19)} | 82,557 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 412 <u>(4)</u> | D | \$ <u>67.3336</u> _{(15) (19)} | 82,145 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 234 <u>(4)</u> | D | \$ <u>67.877</u> _{(16) (20)} | 81,911 | D |
| Common Stock, \$01 par value | 05/08/2015 | <u>S⁽⁴⁾</u> | 55 <u>(4)</u> | D | \$ <u>69.0306</u> ₍₁₇₎ | 81,856 | D |
| | 05/08/2015 | <u>S⁽⁴⁾</u> | 6 <u>(4)</u> | D | | 81,850 | D |

Edgar Filing: ABIOMED INC - Form 4

Common Stock, \$01 par value \$ 69.81
(18)

Common Stock, \$01 par value 05/12/2015 S⁽⁴⁾ 1,602₍₄₎ D \$ 68 80,248 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title Amount or Number of Shares |
| Stock Option (Right to Buy) ⁽¹⁾ | \$ 5.23 | 05/08/2015 | | M | 14,301 | 03/05/2009 ⁽²⁾ 03/05/2019 | Common Stock 14,301 |
| Stock Option (right to buy) ⁽¹⁾ | \$ 10.03 | | | | | 06/03/2011 ⁽²⁾ 06/03/2020 | Common Stock 0 |
| Stock Option (Right to buy) ⁽¹⁾ | \$ 22.44 | | | | | 05/22/2013 ⁽²⁾ 05/22/2022 | Common Stock 0 |
| Stock Option (Right to Buy) ⁽¹⁾ | \$ 23.15 | | | | | 05/14/2014 ⁽²⁾ 05/14/2023 | Common Stock 0 |
| Stock Option (Right to | \$ 21.55 | | | | | 05/14/2015 ⁽³⁾ 05/14/2024 | Common Stock 0 |

Buy) (1)

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Howley Michael G C/O ABIOMED, INC. 22 CHERRY HILL DRIVE DANVERS, MA 01923 | | | VP, Global Sales & Marketing | |

Signatures

/s/ Stephen C. McEvoy (by power of attorney) 05/12/2015

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of option to buy the number of shares of common stock set forth on Table II, Column 7, under the Abiomed, Inc. 2008 Stock Incentive Plan.
- (2) These options become exercisable in annual 25% increments, commencing on the date shown forth in Table II, Column 6.
- (3) These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6.
- (4) Sale of common stock pursuant to reporting owner's 10b5-1 plan.
- (5) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$63.6200 and \$64.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (6) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$64.6200 and \$65.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$65.6750 and \$66.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$66.7000 and \$67.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (9) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$67.7000 and \$68.6600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (10) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$68.7000 and \$69.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (11) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$69.7000 and \$69.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
- (12) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$63.6200 and \$64.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Edgar Filing: ABIOMED INC - Form 4

(13) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$64.6200 and \$65.6100. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(14) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$65.6750 and \$66.6500. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(15) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$66.7000 and \$67.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(16) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$67.7000 and \$68.6600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(17) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$68.7000 and \$69.6900. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(18) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between \$69.7000 and \$69.9600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

(19) To remedy a broker error that occurred in connection with executing the transaction, in accordance with the broker's policy, the reporting person received from the broker an additional payment for the sale of the shares to make the average price per share \$68.0000.

(20) To remedy a broker error that occurred in connection with executing the transaction, in accordance with the broker's policy, the reporting person received from the broker an additional payment for the sale of the shares sold below \$68.0000 per share to make the price per share of such shares \$68.0000 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.